BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12209980)

  • 1. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen.
    Labarrière N; Bretaudeau L; Gervois N; Bodinier M; Bougras G; Diez E; Lang F; Gregoire M; Jotereau F
    Int J Cancer; 2002 Sep; 101(3):280-6. PubMed ID: 12209980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.
    Dieckmann D; Schultz ES; Ring B; Chames P; Held G; Hoogenboom HR; Schuler G
    Int Immunol; 2005 May; 17(5):621-35. PubMed ID: 15824067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
    Mortarini R; Anichini A; Di Nicola M; Siena S; Bregni M; Belli F; Molla A; Gianni AM; Parmiani G
    Cancer Res; 1997 Dec; 57(24):5534-41. PubMed ID: 9407964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
    Berard F; Blanco P; Davoust J; Neidhart-Berard EM; Nouri-Shirazi M; Taquet N; Rimoldi D; Cerottini JC; Banchereau J; Palucka AK
    J Exp Med; 2000 Dec; 192(11):1535-44. PubMed ID: 11104796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
    Michiels A; Breckpot K; Corthals J; Tuyaerts S; Bonehill A; Heirman C; Thielemans K; Aerts JL
    Gene Ther; 2006 Jul; 13(13):1027-36. PubMed ID: 16511519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
    Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF
    Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.